CJC-1295 — a GHRH analog and GH axis signaling in research

CJC-1295 belongs to the class of synthetic GHRH analogs (growth hormone-releasing hormone, growth hormone-releasing hormone). Structurally, it is a modified fragment of the natural GRF(1-29) sequence — the first 29 amino acids of the GHRH molecule, which constitute its biologically active "core". The introduced amino acid substitutions are intended to increase the peptide's resistance to rapid enzymatic degradation, which has made CJC-1295 a convenient tool in the literature for studying somatotropic axis signaling. Peptides of this type are sometimes described as "protein fragments" — short chains that act in the body as one of the languages of cell-to-cell communication.

The primary focus of researchers here is above all the pulsatile nature of pituitary stimulation. The literature distinguishes two variants: with so-called DAC (Drug Affinity Complex) and without DAC. This distinction is key for modeling the signal profile, and not for any use in humans.

Mechanism in brief

The model of action of GHRH and its analogs is based on the lock-and-key principle: the molecule binds to the GHRH receptor (GHRHR) present on the somatotropic cells of the anterior pituitary lobe. This binding constitutes a signal for the release of stored growth hormone (GH). The amino acid substitutions in the CJC-1295 sequence (among others, at positions exposed to cleavage by the DPP-4 peptidase) are meant, in models, to limit the peptide's breakdown. The without-DAC variant has a short half-life, which in research reproduces a profile close to the physiological, short "pulses" of secretion; the with-DAC variant binds to plasma albumin, which prolongs the molecule's presence and shifts the profile toward prolonged stimulation.

What is the subject of research

In the preclinical literature, CJC-1295 appears mainly as a tool for probing the GHRH–GH–IGF-1 axis. The main areas described in the research:

• Activation of the GHRHR receptor in pituitary models — in vitro and animal-model studies analyze the binding of the analog to the somatotroph receptor and the resulting release of GH at the tissue level.
• Pulsatile versus prolonged profile — comparative animal models study how the without-DAC and with-DAC variants differentiate the kinetics of the signal on the GH axis, which makes this pair of molecules a useful system for studying the temporal pattern of secretion itself.
• The GH/IGF-1 axis as a dependent signal — models analyze the downstream cascade in which stimulation of GHRHR translates into changes in the parameters of the somatotropic axis, including IGF-1 as an intermediate marker.
• Combining with ghrelin mimetics — CJC-1295 is sometimes paired in research with Ipamorelin, because both molecules act on two independent pathways: GHRHR and the growth hormone secretagogue receptor (GHS-R1a). Models use this pairing to study the interaction of two distinct mechanisms, and not for any practical application.

The scientific background of this research is the phenomenon of somatopause — the well-documented biological fact that the pulsatile secretion of growth hormone declines with age. Somatopause functions here solely as context explaining why the pulsatile dynamics of the GH axis are an interesting subject of modeling — not as a suggestion of any effect in humans.

Origin and historical context

The GHRH molecule itself was isolated and characterized in the early 1980s, which opened the way to work on its more stable analogs. CJC-1295 was developed in the first decade of the 21st century based on Drug Affinity Complex technology (a Canadian biotechnology background, the company ConjuChem), whose idea was the covalent binding of the peptide to albumin in order to prolong its presence in circulation. Early phase I clinical studies appeared in the literature describing the pharmacokinetics and the effect on the GH/IGF-1 axis in healthy adult volunteers — published as descriptive data on the molecule's behavior, today constituting a point of reference for further preclinical work.

Research specification

In a research context, CJC-1295 most often occurs in the form of a lyophilisate (powder after lyophilization), which is the standard form for stabilizing peptides for laboratory purposes. The quality standard remains confirmation of purity by the HPLC method and identification of the molecule (e.g., mass spectrometry), documented in a certificate of analysis (COA). Storage of the lyophilisate in a research context is carried out under refrigerated conditions and with limited light exposure, in accordance with the general principles for handling peptide materials. Details regarding the physicochemical data and material safety can be found in the safety data sheets section.

Level of evidence

Evidence regarding CJC-1295 comes primarily from in vitro studies and animal models, supplemented by limited, early pharmacokinetic data from human studies describing the molecule's behavior on the GH/IGF-1 axis. Conclusions regarding signal dynamics are modeling in nature and require further research. None of the described observations constitute or can constitute a basis for inferring any use in humans.

For research purposes only. Not for consumption by humans or animals.